Sponsor:
Otsuka Pharmaceutical Development:
Name:
Aspect Study
Protocol Number:
20-AVP-786-306
Summary: The Aspect study is a placebo-controlled study evaluating the safety and efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer’s Type.
Eligibility Criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
50-90
Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT04408755?term=20-AVP-786-306&draw=2&rank=1
Sponsor Website: https://www.otsuka-us.com/
Clinical Trial Studies and those who contribute play a role in the development of new treatments for some of our most common and debilitating diseases and conditions.
Patients who participate in Excell’s clinical trial studies have an opportunity to join the vanguard of scientific research and contribute to the progress, knowledge, and future treatment of medical conditions.
We will provide you with comprehensive information and straightforward answers to your questions regarding the risks and benefits of participating.
Financial compensation may be available to those who qualify and complete visits for Clinical Trial Studies at Excell.
Sponsor:
Alto Neuroscience
Protocol Number:
ALTO-100-201
Summary: The ALTO-100-201 study is evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential study visits.
Eligibility Criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18-70
Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table
Sponsor Website: https://www.altoneuroscience.com/
Sponsor:
Sunovion Pharmaceuticals
Protocol Number:
SEP361-226
Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of SEP361 n adults with Generalized Anixety Disorder.
Eligibility Criteria:
Key Inclusion Criteria:
Key Exclusion Criteria:
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18 to 65
Clinicaltrials.gov Link:
https://clinicaltrials.gov/study/NCT05729373?term=SEP361-226&aggFilters=status:rec&rank=1&tab=table
Sponsor Website:
Sponsor:
Neurocrine
Study Name:
Erudite Study
Protocol Number:
NBI-1065844-CIAS2023
Summary: The Erudite study is evaluating the safety, efficacy, and tolerability of Luvadaxistat in subjects with cognitive impairment associated with schizophrenia.
Eligibility Criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18-50
Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05182476?term=NBI-1065844-CIAS2023&draw=2&rank=1
Sponsor Website: https://www.neurocrine.com/
Sponsor:
Biohaven Pharmaceuticals
Study Name:
Biohaven Study
Protocol Number:
BHV4157-302
Summary: The Biohaven study is a placebo-controlled study evaluating the safety and efficacy of Troriluzole n adults taking an SSRI to treat symptoms of obsessive-compulsive disorder.
Eligibility Criteria:
Key Inclusion Criteria:
Key Exclusion Criteria:
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18 to 65
Clinicaltrials.gov Link:
https://clinicaltrials.gov/ct2/show/NCT04641143?term=BHV4157-302&draw=2&rank=1
Sponsor Website:
Sponsor:
AbbVie
Name:
Periscope Study
Protocol Number:
3110-305-002
Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of Ubrogepant in acute treatment of migraine with or without aura in children and adolescents.
Eligibility Criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
12-17
Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/study/NCT05125302?term=3110-305-002&draw=2&rank=2
Alzheimer’s disease is a brain disorder that gets worse over time. It’s characterized by changes in the brain that lead to deposits of certain proteins. Alzheimer’s disease causes the brain to shrink and brain cells to eventually die. Alzheimer’s disease is the most common cause of dementia — a gradual decline in memory, thinking, behavior and social skills. These changes affect a person’s ability to function.
People with Alzheimer’s disease may: